Top

Published in:

Open Access 01-12-2023 | Empagliflozin | Review

Empagliflozin: a potential anticancer drug

Authors: Wenwen Wu, Yanyan Wang, Jun Xie, Shaohua Fan

Published in: Discover Oncology | Issue 1/2023

Abstract

Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is a highly effective and well-tolerated antidiabetic drug. In addition to hypoglycemic effects, empagliflozin has many other effects, such as being hypotensive and cardioprotective. It also has anti-inflammatory and antioxidative stress effects in diabetic nephropathy. Several studies have shown that empagliflozin has anticancer effects. SGLT2 is expressed in a variety of cancer cell lines. The SGLT2 inhibitor empagliflozin has significant inhibitory effects on certain types of tumor cells, such as inhibition of proliferation, migration and induction of apoptosis. In conclusion, empagliflozin has promising applications in cancer therapy as a drug for the treatment of diabetes and heart failure. This article provides a brief review of the anticancer effects of empagliflozin.

Borse SP, Chhipa AS, Sharma V, Singh DP, Nivsarkar M. Management of type 2 diabetes: current strategies, unfocussed aspects, challenges, and alternatives. Med Princ Pract. 2021;30(2):109–21. https://doi.org/10.1159/000511002.CrossRefPubMed

Faridi U, Al-Mutairi F, Parveen H, Khateeb S. An in-vitro and in silico anticancer study of FDA approved antidiabetic drugs Glimepiride and Empagliflozin. Int J Life Sci Pharma Res. 2020;10(2):52–7. https://doi.org/10.22376/ijpbs/lpr.2020.10.2.L52-57.CrossRef

Padda IS, Mahtani AU, Parmar M. Sodium-glucose transport protein 2 (SGLT2) inhibitors. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2022.

Mascolo A, Di Napoli R, Balzano N, Cappetta D, Urbanek K, De Angelis A, et al. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary. Front Cardiovasc Med. 2022;9:1010693. https://doi.org/10.3389/fcvm.2022.1010693.CrossRefPubMedPubMedCentral

Frampton JE, Empagliflozin. A review in type 2 diabetes. Drugs. 2018;78(10):1037–48. https://doi.org/10.1007/s40265-018-0937-z.CrossRefPubMed

Li J, Liu H, Takagi S, Nitta K, Kitada M, Srivastava SP, et al. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules. JCI Insight. 2020;5(6):e129034. https://doi.org/10.1172/jci.insight.129034.CrossRefPubMedPubMedCentral

Kabel AM, Estfanous RS, Alrobaian MM. Targeting oxidative stress, proinflammatory cytokines, apoptosis and toll like receptor 4 by empagliflozin to ameliorate bleomycin-induced lung fibrosis. Respir Physiol Neurobiol. 2020;273:103316. https://doi.org/10.1016/j.resp.2019.103316.CrossRefPubMed

Ashrafi Jigheh Z, Ghorbani Haghjo A, Argani H, Roshangar L, Rashtchizadeh N, Sanajou D, et al. Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis. Iran J Basic Med Sci. 2019;22(4):384–90. https://doi.org/10.22038/ijbms.2019.31788.7651.CrossRefPubMedPubMedCentral

Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res. 2015;47(9):686–92. https://doi.org/10.1055/s-0034-1395609.CrossRefPubMed

10.

Wu X, Li H, Wan Z, Wang R, Liu J, Liu Q, et al. The combination of ursolic acid and empagliflozin relieves diabetic nephropathy by reducing inflammation, oxidative stress and renal fibrosis. Biomed Pharmacother. 2021;144:112267. https://doi.org/10.1016/j.biopha.2021.112267.CrossRefPubMed

11.

Iannantuoni F, de Marañon M, Diaz-Morales A, Falcon N, Bañuls R, Abad-Jimenez C. The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes. J Clin Med. 2019;8(11):1814. https://doi.org/10.3390/jcm8111814.CrossRefPubMedPubMedCentral

12.

Aragón-Herrera A, Feijóo-Bandín S, Otero Santiago M, Barral L, Campos-Toimil M, Gil-Longo J, et al. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 2019;170:113677. https://doi.org/10.1016/j.bcp.2019.113677.CrossRefPubMed

13.

Yaribeygi H, Butler AE, Atkin SL, Katsiki N, Sahebkar A. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways. J Cell Physiol. 2018;234(1):223–30. https://doi.org/10.1002/jcp.26851.CrossRefPubMed

14.

Wright EM. SGLT2 and cancer. Pflugers Arch. 2020;472(9):1407–14. https://doi.org/10.1007/s00424-020-02448-4.CrossRefPubMedPubMedCentral

15.

Shoda K, Tsuji S, Nakamura S, Egashira Y, Enomoto Y, Nakayama N, et al. Canagliflozin inhibits glioblastoma growth and proliferation by activating AMPK. Cell Mol Neurobiol. 2023;43(2):879–92. https://doi.org/10.1007/s10571-022-01221-8.CrossRefPubMed

16.

Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, et al. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer. 2018;142(8):1712–22. https://doi.org/10.1002/ijc.31193.CrossRefPubMed

17.

Xie Z, Wang F, Lin L, Duan S, Liu X, Li X, et al. An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells. Cancer Lett. 2020;495:200–10. https://doi.org/10.1016/j.canlet.2020.09.005.CrossRefPubMed

18.

Eliaa SG, Al-Karmalawy AA, Saleh RM, Elshal MF. Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mTOR pathway and inhibition of calmodulin: in vitro and molecular docking studies. ACS Pharmacol Transl Sci. 2020;3(6):1330–8. https://doi.org/10.1021/acsptsci.0c00144.CrossRefPubMedPubMedCentral

19.

Abdelhamid AM, Saber S, Youssef ME, Gaafar AGA, Eissa H, Abd-Eldayem MA, et al. Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: emerging approach for new application. Biomed Pharmacother. 2022;145:112455. https://doi.org/10.1016/j.biopha.2021.112455.CrossRefPubMed

20.

Dutka M, Bobiński R, Francuz T, Garczorz W, Zimmer K, Ilczak T, et al. SGLT-2 inhibitors in cancer treatment-mechanisms of action and emerging new perspectives. Cancers (Basel). 2022;14(23):5811. https://doi.org/10.3390/cancers14235811.CrossRefPubMed

21.

Madaan T, Husain I, Akhtar M, Najmi AK. Exploring novel pharmacotherapeutic applications and repurposing potential of sodium glucose CoTransporter 2 inhibitors. Clin Exp Pharmacol Physiol. 2018;45:897–907. https://doi.org/10.1111/1440-1681.12963.CrossRef

22.

Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–90. https://doi.org/10.1097/CM9.0000000000002108.CrossRefPubMed

23.

Wojtynek NE, Mohs AM. Image-guided tumor surgery: the emerging role of nanotechnology. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12(4):e1624. https://doi.org/10.1002/wnan.1624.CrossRefPubMedPubMedCentral

24.

Chen HHW, Kuo MT. Improving radiotherapy in cancer treatment: promises and challenges. Oncotarget. 2017;8(37):62742–58. https://doi.org/10.18632/oncotarget.18409.CrossRefPubMedPubMedCentral

25.

Sørensen BS, Horsman MR. Tumor hypoxia: impact on radiation therapy and molecular pathways. Front Oncol. 2020;10:562. https://doi.org/10.3389/fonc.2020.00562.CrossRefPubMedPubMedCentral

26.

Haque M, Shakil MS, Mahmud KM. The promise of nanoparticles-based radiotherapy in cancer treatment. Cancers (Basel). 2023;15(6):1892. https://doi.org/10.3390/cancers15061892.CrossRefPubMed

27.

Wang Y, Wei Y, Wu Y, Zong Y, Song Y, Pu S, et al. Multifunctional nano-realgar hydrogel for enhanced glioblastoma synergistic chemotherapy and radiotherapy: a new paradigm of an old drug. Int J Nanomedicine. 2023;18:743–63. https://doi.org/10.2147/IJN.S394377.CrossRefPubMedPubMedCentral

28.

Sun Q, Melino G, Amelio I, Jiang J, Wang Y, Shi Y. Recent advances in cancer immunotherapy. Discov Oncol. 2021;12(1):27. https://doi.org/10.1007/s12672-021-00422-9.CrossRefPubMedPubMedCentral

29.

Li W, Peng A, Wu H, Quan Y, Li Y, Lu L, et al. Anti-cancer nanomedicines: a revolution of tumor immunotherapy. Front Immunol. 2020;11:601497. https://doi.org/10.3389/fimmu.2020.601497.CrossRefPubMedPubMedCentral

30.

Liu D, Gao S, Zhai Y, Yang X, Zhai G. Research progress of tumor targeted drug delivery based on PD-1/PD-L1. Int J Pharm. 2022;616:121527. https://doi.org/10.1016/j.ijpharm.2022.121527.CrossRefPubMed

31.

Tang Y, Chang Q, Chen G, Zhao X, Huang G, Wang T, et al. Tumor immunosuppression relief via acidity modulation combined PD-L1 siRNA for enhanced immunotherapy. Biomater Adv. 2023;150:213425. https://doi.org/10.1016/j.bioadv.2023.213425.CrossRefPubMed

32.

Song P, Wang B, Pan Q, Jiang T, Chen X, Zhang M, et al. GE11-modified carboxymethyl chitosan micelles to deliver DOX·PD-L1 siRNA complex for combination of ICD and immune escape inhibition against tumor. Carbohydr Polym. 2023;312:120837. https://doi.org/10.1016/j.carbpol.2023.120837.CrossRefPubMed

33.

Ma X, Fang W, Wang D, Shao N, Chen J, Nie T, et al. Nanomaterial-based antivascular therapy in the multimodal treatment of cancer. Pharmaceutics. 2023;15(4):1207. https://doi.org/10.3390/pharmaceutics15041207.CrossRefPubMedPubMedCentral

34.

Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188–96. https://doi.org/10.1016/j.ejphar.2018.07.034.CrossRefPubMed

35.

Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79. https://doi.org/10.1016/j.ejpb.2015.03.018.CrossRefPubMed

36.

Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys. 2005;63(3):655–66. https://doi.org/10.1016/j.ijrobp.2005.06.032.CrossRefPubMedPubMedCentral

37.

Liu N, Zhang R, Shi Q, Jiang H, Zhou Q. Intelligent delivery system targeting PD-1/PD-L1 pathway for cancer immunotherapy. Bioorg Chem. 2023;136:106550. https://doi.org/10.1016/j.bioorg.2023.106550.CrossRefPubMed

38.

Wang Z, Wu X. Study and analysis of antitumor resistance mechanism of PD-1/PD-L1 immune checkpoint blocker. Cancer Med. 2020;9(21):8086–121. https://doi.org/10.1002/cam4.3410.CrossRefPubMedPubMedCentral

39.

Wang NF, Jue TR, Holst J, Gunter JH. Systematic review of antitumour efficacy and mechanism of metformin activity in prostate cancer models. BJUI Compass. 2023;4:44–58. https://doi.org/10.1002/bco2.187.CrossRefPubMed

40.

Jin P, Jiang J, Zhou L, Huang Z, Qin S, Chen HN, et al. Disrupting metformin adaptation of liver cancer cells by targeting the TOMM34/ATP5B axis. EMBO Mol Med. 2022;14(12):e16082. https://doi.org/10.15252/emmm.202216082.CrossRefPubMedPubMedCentral

41.

Zhan Q, Yi K, Cui X, Li X, Yang S, Wang Q, et al. Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy. Neuro Oncol. 2022;24(11):1871–83. https://doi.org/10.1093/neuonc/noac071.CrossRefPubMedPubMedCentral

42.

Zheng Y, Zhang H, Sun H. Metformin inhibits the proliferation and invasion of ovarian cancer cells by suppressing tripartite motif-containing 37-induced tumor necrosis factor receptor-associated factor 2 ubiquitination. Cancer Sci. 2022;113(11):3776–86. https://doi.org/10.1111/cas.15524.CrossRefPubMedPubMedCentral

43.

Pereira FV, Melo ACL, Low JS, de Castro ÍA, Braga TT, Almeida DC, et al. Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. Oncotarget. 2018;9(40):25808–25. https://doi.org/10.18632/oncotarget.25380.CrossRefPubMedPubMedCentral

44.

Afzal MZ, Mercado RR, Shirai K. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma. J Immunother Cancer. 2018;6(1):64. https://doi.org/10.1186/s40425-018-0375-1.CrossRefPubMedPubMedCentral

45.

Laskar J, Bhattacharjee K, Sengupta M, Choudhury Y. Anti-diabetic drugs: cure or risk factors for cancer? Pathol Oncol Res. 2018;24(4):745–55. https://doi.org/10.1007/s12253-018-0402-z.CrossRefPubMed

46.

Kuang H, Liao L, Chen H, Kang Q, Shu X, Wang Y. Therapeutic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma. Med Sci Monit. 2017;23:3737–45. https://doi.org/10.12659/msm.902530.CrossRefPubMedPubMedCentral

47.

Sabaa M, Sharawy MH, El-Sherbiny M, Said E, Salem HA, Ibrahim TM. Canagliflozin interrupts mTOR-mediated inflammatory signaling and attenuates DMBA-induced mammary cell carcinoma in rats. Biomed Pharmacother. 2022;155:113675. https://doi.org/10.1016/j.biopha.2022.113675.CrossRefPubMed

48.

Sundström K, Elfström KM. Advances in cervical cancer prevention: efficacy, effectiveness, elimination? PLoS Med. 2020;17(1):e1003035. https://doi.org/10.1371/journal.pmed.1003035.CrossRefPubMedPubMedCentral

49.

Yuan Y, Cai X, Shen F, Ma F. HPV post-infection microenvironment and cervical cancer. Cancer Lett. 2021;497:243–54. https://doi.org/10.1016/j.canlet.2020.10.034.CrossRefPubMed

50.

Smothers AR, Henderson JR, O’Connell JJ, Stenbeck JM, Dean D, Harvey TG, et al. Efficacy and selectivity of tumor-treating field therapy for triple-negative breast cancer cells via in-house delivery device. Discov Oncol. 2023;14(1):34. https://doi.org/10.1007/s12672-023-00647-w.CrossRefPubMedPubMedCentral

51.

Ge J, Zuo W, Chen Y, Shao Z, Yu K. The advance of adjuvant treatment for triple-negative breast cancer. Cancer Biol Med. 2021;19(2):187–201. https://doi.org/10.20892/j.issn.2095-3941.2020.0752.CrossRefPubMedPubMedCentral

52.

Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017;18(10):1360–72. https://doi.org/10.1016/S1470-2045.CrossRefPubMedPubMedCentral

53.

Sohail M, Sun Z, Li Y, Gu X, Xu H. Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy. Expert Rev Anticancer Ther. 2021;21(12):1385–98. https://doi.org/10.1080/14737140.2021.1991316.CrossRefPubMed

54.

Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol. 2020;38(5):423–33. https://doi.org/10.1200/JCO.19.00368.CrossRefPubMed

55.

Anker SD, Butler J. Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle. ESC Heart Fail. 2018;5(4):549–51. https://doi.org/10.1002/ehf2.12345.CrossRefPubMedPubMedCentral

56.

Mustroph J, Wagemann O, Lücht CM, Trum M, Hammer KP, Sag CM, et al. Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018;5(4):642–8. https://doi.org/10.1002/ehf2.12336.CrossRefPubMedPubMedCentral

57.

Nalla LV, Khairnar A. Empagliflozin mediated mir-128-3p upregulation promotes differentiation of hypoxic cancer stem-like cells in breast cancer. Eur J Pharmacol. 2023;943:175565. https://doi.org/10.1016/j.ejphar.2023.175565.CrossRefPubMed

58.

Alzahrani B, Iseli TJ, Hebbard LW. Non-viral causes of liver cancer: does obesity led inflammation play a role? Cancer Lett. 2014;345(2):223–9. https://doi.org/10.1016/j.canlet.2013.08.036.CrossRefPubMed

59.

Ohkuma T, Peters SAE, Woodward M. Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events. Diabetologia. 2018;61(10):2140–54.CrossRefPubMedPubMedCentral

60.

Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, Malek M, Reza Babaei M, Zamani F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther. 2021;12(3):843–61. https://doi.org/10.1007/s13300-021-01011-3.CrossRefPubMedPubMedCentral

61.

Maehara O, Ohnishi S, Asano A, Suda G, Natsuizaka M, Nakagawa K, et al. Metformin regulates the expression of CD133 through the AMPK-CEBPβ pathway in hepatocellular carcinoma cell lines. Neoplasia. 2019;21(6):545–56. https://doi.org/10.1016/j.neo.2019.03.007.CrossRefPubMedPubMedCentral

62.

Tsai JJ, Chen JH, Chen CH, Chung JG, Hsu FT. Apoptosis induction and ERK/NF-κB inactivation are associated with magnolol-inhibited tumor progression in hepatocellular carcinoma in vivo. Environ Toxicol. 2020;35(2):167–75. https://doi.org/10.1002/tox.22853.CrossRefPubMed

63.

Chen XS, Cui JR, Meng XL, Wang SH, Wei W, Gao YL, et al. Angiotensin-(1–7) ameliorates sepsis-induced cardiomyopathy by alleviating inflammatory response and mitochondrial damage through the NF-κB and MAPK pathways. J Transl Med. 2023;21(1):2. https://doi.org/10.1186/s12967-022-03842-5.CrossRefPubMedPubMedCentral

64.

Zhang H, Deng X, Zhou C, Wu W, Zhang H. Deoxynivalenol induces inflammation in IPEC-J2 cells by activating p38 mapk and Erk1/2. Toxins (Basel). 2020;12(3):180. https://doi.org/10.3390/toxins12030180.CrossRefPubMedPubMedCentral

65.

Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004;68(2):320–44. https://doi.org/10.1128/MMBR.68.2.320-344.200.CrossRefPubMedPubMedCentral

66.

Lin Z, Li S, Guo P, Wang L, Zheng L, Yan Z, et al. Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathways. Life Sci. 2019;218:197–204. https://doi.org/10.1016/j.lfs.2018.12.038.CrossRefPubMed

67.

Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783–91. https://doi.org/10.1097/CM9.0000000000001474.CrossRefPubMed

68.

Zhou G. Tobacco, air pollution, environmental carcinogenesis, and thoughts on conquering strategies of lung cancer. Cancer Biol Med. 2019;16(4):700–13. https://doi.org/10.20892/j.issn.2095-3941.2019.0180.CrossRefPubMedPubMedCentral

69.

Fillon M. Pairing smoking cessation with lung cancer screening may save lives. CA Cancer J Clin. 2021;71(4):283–4. https://doi.org/10.3322/caac.21675.CrossRefPubMed

70.

Sinha S, Sonali, Garg V, Thapa S, Singh S, Chauhan M, et al. Empagliflozin containing chitosan-alginate nanoparticles in orodispersible film: Preparation, characterization, pharmacokinetic evaluation and its in-vitro anticancer activity. Drug Dev Ind Pharm. 2022;48(7):279–91. https://doi.org/10.1080/03639045.2022.2108829.CrossRefPubMed

71.

Koepsell H. The Na⁺-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacol Ther. 2017;170:148–65. https://doi.org/10.1016/j.pharmthera.2016.10.017.CrossRefPubMed

Title: Empagliflozin: a potential anticancer drug
Authors: Wenwen Wu
Yanyan Wang
Jun Xie
Shaohua Fan
Publication date: 01-12-2023
Publisher: Springer US
Keywords: Empagliflozin
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Cervical Cancer
Cervical Cancer
Metformin
Cancer Therapy
Published in: Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-023-00719-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

SDH mutations, as potential predictor of chemotherapy prognosis in small cell lung cancer patients

A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy

Classification and function of γδT cells and its research progress in anti-glioblastoma

Hereditary diffuse gastric cancer in a Japanese family with CDH1 mutation three case reports

Modern treatment strategies in pediatric oncology and hematology

Preliminary results from the EMoLung clinical study showing early lung cancer detection by the LC score

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials